CatalYm, a German biotech company specializing in cancer immunotherapy, has recently secured $150 million in a Series D funding round. This significant financial boost follows promising early-stage clinical data for its lead monoclonal antibody candidate, visugromab. The funds will be instrumental in expanding phase 2b trials, particularly targeting checkpoint-naive and second-line treatment settings for various solid tumors.
Background of CatalYm
CatalYm was founded in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg. The company focuses on developing innovative therapies to transform cancer treatment by harnessing the body’s immune system. Since its inception, CatalYm has successfully raised substantial funding across multiple rounds,
